Bristol-Myers Squibb reveals NULOJIX data CSL Recruitment NULOJIX is the first selective T-cell costimulation blocker for the prophylaxis of organ rejection in adults with Epstein-Barr Virus who are having a kidney transplant in conjunction with basiliximab induction, mycophenolate mofetil, ... Bristol-Myers Squibb announces positive four-year Nujolix data |
